肺癌患者血清sIL-6R检测的临床研究  

Clinical study on serum sIL-6R of lung cancer cases

作　　者：王静[1] 张茂林[2] 马利军[3] 孙培宗[1] 王俊平[1] 董君 张罗献[3] 

机构地区：[1]河南医科大学第一附属医院呼吸内科,郑州450052 [2]河南医科大学无机化学教研室,郑州450052 [3]河南省人民医院呼吸内科,郑州450003

出　　处：《河南医科大学学报》2000年第3期255-257,共3页Journal of Henan Medical University

基　　金：郑州市科委科技攻关项目!990 12 43

摘　　要：目的 :通过检测肺癌患者在不同临床阶段血清中sIL 6R的水平 ,探索sIL 6R在肺癌患者体内变化的规律 ,为估计病情、判断预后寻找一个客观指标。方法 :Ⅰ期和Ⅳ期肺癌患者各 2 0例 ,对照组 2 0例 ,分别抽取空腹血离心后 ,留取血清 ,用ELISA方法检测。结果 :对照组血清sIL 6R水平为 (46 .83± 6 .70 ) μg/L ;Ⅰ期肺癌组血清sIL 6R水平为 (5 8.6 3± 3.94) μg/L ;Ⅳ期肺癌组血清sIL 6R水平为 (6 9.2 3± 18.73) μg/L ,Ⅰ期和Ⅳ期肺癌组血清sIL 6R水平均明显高于对照组 (P <0 .0 0 1) ;Ⅳ期肺癌组血清sIL 6R水平又明显高于Ⅰ期肺癌组 (P <0 .0 0 1) ;3组之间经方差分析和q检验 ,差异有显著性 (P <0 0 0 1)。结论 :肺癌患者体内存在着sIL 6R的异常表达。Ⅳ期肺癌患者血清中sIL 6R水平高于Ⅰ期患者。当病情进展、病灶范围增大时 ,体内sIL 6R表达增多。提示sIL 6R可能是肺癌患者预后不良的指标。Aim:In order to find an objective indicator of estimating the state of lung carcer and judging its prognosis ,and the lever of serum sIL 6R in different stages of lung carcer cases were measured. Methods : 20 cases of lung carcer in stage Ⅰ and 20 cases in stage Ⅳ were selected as two test groups ,and the control group also contained 20 cases . Their blood samples were centrifuged to seperate the serum which were used to be detested the levels of sIL 6R by ELISA. Results: The levels of sIL 6R of stage Ⅰ group, stage Ⅳ group and the control group were (58.63±3.94)μg/L , (69.23±18.37)μg/L and (46.83±6.70)μg/L , respectively. Those in the test groups were obviously higher than that in the control group ( P <0.001).That in stage Ⅳ group was obviously higher than that in stage Ⅰ ( P <0.001) . The analysis of variance and q test verified that the differences between the three groups were significant . Conclusion: The level of sIL 6R of lung cancer cases was higher than that of the control group, which indicated that the lung cancer patients have abnormal expression of sIL 6R . The stage Ⅳ cases had higher level of sIL 6R than that of the stage Ⅰ group, and the worse the illness is, the higher the expression of sIL 6R is. The level of sIL 6R could be probably considered as an objective indicator of lung cancer's prognosis.

关 键 词：肺肿瘤 可溶性白细胞介素-6受体 血清诊断 

分 类 号：R734.204[医药卫生—肿瘤]